Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Frequently Asked Questions Prohibited List Click on the question to drop down the answer
It found a 20% reduction in major adverse cardiovascular events - heart attacks, strokes, and cardiovascular death - with FDA-approved Wegovy in a population with established cardiovascular disease and overweight or obesity
mental and emotional factors play a significant role too
Recent Developments In February 2026 , Pfizer announced positive Phase 2b trial results for its ultra-long-acting injectable GLP-1 (PF-08653944), demonstrating significant weight loss with monthly dosing
US$ 20.78
US$ 21.65
US$ 20.54
US$ 21.69
